Stocks · News reference
Armata Announces Significant Clinical, Regulatory, Manufacturing And Operational Progress Supporting Advancement Of AP-SA02 Toward Planned Phase 3 Superiority Study For Adjunct Treatment Of Complicated Bacteremia
FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meetingFour AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.45) by 38.64 percent. This is a 40 percent increase over losses of $(0.45) per share
Armata Pharmaceuticals Announces Promotion Of David House To CFO
Why Is Armata Pharma Stock Gaining Monday?
ARMP stock jumps 10% as Armata Pharmaceuticals prepares its AP-SA02 multi-phage candidate for a pivotal Phase 3 trial in late 2026.